RESPONSE TO NIVOLUMAB AS ≥3rd LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS
Hematological Oncology - United Kingdom
doi 10.1002/hon.174_2631
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley